Search details
1.
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study.
Future Oncol
; 19(23): 1601-1611, 2023 Jul.
Article
in English
| MEDLINE | ID: mdl-37577810
2.
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial.
Lancet Oncol
; 23(7): 876-887, 2022 07.
Article
in English
| MEDLINE | ID: mdl-35636444
3.
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?
Br J Cancer
; 127(5): 957-967, 2022 09.
Article
in English
| MEDLINE | ID: mdl-35665778
4.
KDR genetic predictor of toxicities induced by sorafenib and regorafenib.
Pharmacogenomics J
; 22(5-6): 251-257, 2022 12.
Article
in English
| MEDLINE | ID: mdl-35484400
5.
CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies.
Br J Cancer
; 125(6): 839-845, 2021 09.
Article
in English
| MEDLINE | ID: mdl-34253871
6.
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO.
Br J Cancer
; 124(1): 183-190, 2021 01.
Article
in English
| MEDLINE | ID: mdl-33024268
7.
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
Oncologist
; 26(4): 302-309, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33336844
8.
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Lancet Oncol
; 21(4): 497-507, 2020 04.
Article
in English
| MEDLINE | ID: mdl-32164906
9.
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
BMC Cancer
; 20(1): 683, 2020 Jul 22.
Article
in English
| MEDLINE | ID: mdl-32698790
10.
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.
Br J Cancer
; 118(7): 955-965, 2018 04.
Article
in English
| MEDLINE | ID: mdl-29531324
11.
Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program.
Oncologist
; 23(10): 1178-1187, 2018 10.
Article
in English
| MEDLINE | ID: mdl-29739893
12.
Liquid chromatographic/electrospray ionization quadrupole/time of flight tandem mass spectrometric study of polyphenolic composition of different Vaccinium berry species and their comparative evaluation.
Anal Bioanal Chem
; 409(5): 1347-1368, 2017 Feb.
Article
in English
| MEDLINE | ID: mdl-27847974
13.
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer.
Br J Cancer
; 114(1): 30-6, 2016 Jan 12.
Article
in English
| MEDLINE | ID: mdl-26575603
14.
Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer.
Oncologist
; 21(8): 988-94, 2016 08.
Article
in English
| MEDLINE | ID: mdl-27382031
15.
TRIBE2 results and toxicity - Authors' reply.
Lancet Oncol
; 21(6): e300-e301, 2020 06.
Article
in English
| MEDLINE | ID: mdl-32502452
16.
Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer: A Nonrandomized Controlled Trial.
JAMA Netw Open
; 7(4): e245635, 2024 Apr 01.
Article
in English
| MEDLINE | ID: mdl-38592721
17.
Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials.
Eur J Cancer
; 184: 106-116, 2023 05.
Article
in English
| MEDLINE | ID: mdl-36913832
18.
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients.
Tumori
; 109(5): 481-489, 2023 Oct.
Article
in English
| MEDLINE | ID: mdl-36609197
19.
Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials.
Eur J Cancer
; 189: 112910, 2023 08.
Article
in English
| MEDLINE | ID: mdl-37301718
20.
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study.
J Immunother Cancer
; 11(4)2023 04.
Article
in English
| MEDLINE | ID: mdl-37085190